BioWorld Asia

April 7, 2004

Australia-Based Norwood Seeks IPO On London's AIM Exchange

An Australian company with a U.S. development partner is expecting to float on the Alternative Investment Market in London to raise £15 million (US$27.2 million). (BioWorld International) Read More

Ablynx Completes EUR25M Series B Financing For Nanobody Platform

HIV Research Could Benefit From Immune System Model

Cilian, Evotec Neuroscience Reel In Venture Funding Totaling EUR30M

Ardana Signs New Zentaris Deal, Gains Global Rights To Teverelix

EU Finalizes Environmental Law That Could Leave Biotech Liable

Gastrotech Acquires Lilly Deal Through Purchase Of IP Assets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...